Bipolar Disorder In Remission — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bipolar disorder in remission. 395 active patents protecting 5 drugs from 5+ originators. First major cliff: 2026. Daily refresh.

5
Approved drugs
395
Active US patents
60/100
Avg vulnerability
$3.3B
Annual revenue covered

Originators in Bipolar Disorder In Remission

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Otsuka/BMS) 214 patents Johnson & Johnson (Janssen) 110 patents Eli Lilly 56 patents GSK 8 patents Novartis AG (originally Geigy) 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bipolar disorder in remission. Each bar = one year. Y-axis scaled to peak year (76 patents).

28
26
35
27
20
28
63
29
48
30
76
31
30
32
45
33
8
34
20
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Abilify
aripiprazole
 Generic (originally Otsuka/BMS) 214 61 $3.0B 2026-07-28
Risperdal
risperidone
 Johnson & Johnson (Janssen) 110 56 — 2026-06-26
Zyprexa
olanzapine
 Eli Lilly 56 64 $300M 2031-08-23
Lamictal
lamotrigine
 GSK 8 64 — 2029-01-07
Tegretol
carbamazepine
 Novartis AG (originally Geigy) 7 55 — 2028-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
12194035 Zyprexa method of use 81 2031-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05

Related